Business
Currency:USD
2024/FY
Stock NameRevenueRatio
Developing next-generation complement therapeutics for patients living with severe autoimmune6.24M100.00%
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States6.24M100.00%